|
|
Liptis, an international pharmaceutical company,
is dedicated to delivering innovative medicines to millions of patients around the world.
We are pleased to announce the availability of Cavigen.
|
|
|
|
 |
 |
|
|
|
Liptis, an international pharmaceutical company, is dedicated to delivering innovative medicines to millions of patients around the world. We are pleased to announce the availability of Cavigen.
Cavigen is an oral therapy for sexual dysfunction. It has an advantage over the available medications in that it treats the root of the problem of erectile dysfunction which is the deficiency of libido.
Cavigen is the first aphrodisiac in the world to be patented in The United States of America in 1996.
It is approved by the FDA and has been marketed successfully in more than 15 countries including the USA since 1997.
Cavigen can be used by a wide variety of patients with concurrent diseases and concomitant therapies as it is devoid of any drug-drug or drug-disease interactions. It is a remarkably safe product, suitable for long-term use.
Cavigen is a notable innovation in the treatment of erectile dysfunction without the drawbacks of the current medications.
| | |
|
